Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: Clinical outcomes

Atsuhiro Kumabe, Noboru Fukuhara, Takuji Utsunomiya, Takatsugu Kawase, Kunihiro Iwata, Yukinori Okada, Shinya Sutani, Toshio Ohashi, Mototsugu Oya, Naoyuki Shigematsu

研究成果: Article

抄録

Background: We report the feasibility and treatment outcomes of image-guided three-dimensional conformal arc radiotherapy (3D-CART) using a C-arm linear accelerator with a computed tomography (CT) on-rail system for localized prostate cancer. Methods and materials: Between 2006 and 2011, 282 consecutive patients with localized prostate cancer were treated with in-room CT-guided 3D-CART. Biochemical failure was defined as a rise of at least 2.0 ng/ml beyond the nadir prostate-specific antigen level. Toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Results: A total of 261 patients were analyzed retrospectively (median follow-up: 61.6 months). The median prescribed 3D-CART dose was 82 Gy (2 Gy/fraction, dose range: 78-86 Gy), and 193 of the patients additionally received hormonal therapy. The 5-year overall survival rate was 93.9 %. Among low-, intermediate-, and high-risk patients, 5-year rates of freedom from biochemical failure were 100, 91.5 and 90.3 %, respectively. Rates of grade 2-3 late gastrointestinal and genitourinary toxicities were 2.3 and 11.4 %, respectively. No patient experienced late grade 4 or higher toxicity. Conclusions: In-room CT-guided 3D-CART was feasible and effective for localized prostate cancer. Treatment outcomes were comparable to those previously reported for intensity-modulated radiotherapy.

元の言語English
記事番号208
ジャーナルRadiation Oncology
10
発行部数1
DOI
出版物ステータスPublished - 2015 10 12

Fingerprint

Conformal Radiotherapy
Particle Accelerators
Prostatic Neoplasms
Tomography
Intensity-Modulated Radiotherapy
National Cancer Institute (U.S.)
Prostate-Specific Antigen
Terminology
Survival Rate

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

これを引用

Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer : Clinical outcomes. / Kumabe, Atsuhiro; Fukuhara, Noboru; Utsunomiya, Takuji; Kawase, Takatsugu; Iwata, Kunihiro; Okada, Yukinori; Sutani, Shinya; Ohashi, Toshio; Oya, Mototsugu; Shigematsu, Naoyuki.

:: Radiation Oncology, 巻 10, 番号 1, 208, 12.10.2015.

研究成果: Article

@article{c457e58ee6b0496cb5c3dca46915cddf,
title = "Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: Clinical outcomes",
abstract = "Background: We report the feasibility and treatment outcomes of image-guided three-dimensional conformal arc radiotherapy (3D-CART) using a C-arm linear accelerator with a computed tomography (CT) on-rail system for localized prostate cancer. Methods and materials: Between 2006 and 2011, 282 consecutive patients with localized prostate cancer were treated with in-room CT-guided 3D-CART. Biochemical failure was defined as a rise of at least 2.0 ng/ml beyond the nadir prostate-specific antigen level. Toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Results: A total of 261 patients were analyzed retrospectively (median follow-up: 61.6 months). The median prescribed 3D-CART dose was 82 Gy (2 Gy/fraction, dose range: 78-86 Gy), and 193 of the patients additionally received hormonal therapy. The 5-year overall survival rate was 93.9 {\%}. Among low-, intermediate-, and high-risk patients, 5-year rates of freedom from biochemical failure were 100, 91.5 and 90.3 {\%}, respectively. Rates of grade 2-3 late gastrointestinal and genitourinary toxicities were 2.3 and 11.4 {\%}, respectively. No patient experienced late grade 4 or higher toxicity. Conclusions: In-room CT-guided 3D-CART was feasible and effective for localized prostate cancer. Treatment outcomes were comparable to those previously reported for intensity-modulated radiotherapy.",
keywords = "C-arm, Prostate cancer, Radiotherapy",
author = "Atsuhiro Kumabe and Noboru Fukuhara and Takuji Utsunomiya and Takatsugu Kawase and Kunihiro Iwata and Yukinori Okada and Shinya Sutani and Toshio Ohashi and Mototsugu Oya and Naoyuki Shigematsu",
year = "2015",
month = "10",
day = "12",
doi = "10.1186/s13014-015-0515-4",
language = "English",
volume = "10",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer

T2 - Clinical outcomes

AU - Kumabe, Atsuhiro

AU - Fukuhara, Noboru

AU - Utsunomiya, Takuji

AU - Kawase, Takatsugu

AU - Iwata, Kunihiro

AU - Okada, Yukinori

AU - Sutani, Shinya

AU - Ohashi, Toshio

AU - Oya, Mototsugu

AU - Shigematsu, Naoyuki

PY - 2015/10/12

Y1 - 2015/10/12

N2 - Background: We report the feasibility and treatment outcomes of image-guided three-dimensional conformal arc radiotherapy (3D-CART) using a C-arm linear accelerator with a computed tomography (CT) on-rail system for localized prostate cancer. Methods and materials: Between 2006 and 2011, 282 consecutive patients with localized prostate cancer were treated with in-room CT-guided 3D-CART. Biochemical failure was defined as a rise of at least 2.0 ng/ml beyond the nadir prostate-specific antigen level. Toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Results: A total of 261 patients were analyzed retrospectively (median follow-up: 61.6 months). The median prescribed 3D-CART dose was 82 Gy (2 Gy/fraction, dose range: 78-86 Gy), and 193 of the patients additionally received hormonal therapy. The 5-year overall survival rate was 93.9 %. Among low-, intermediate-, and high-risk patients, 5-year rates of freedom from biochemical failure were 100, 91.5 and 90.3 %, respectively. Rates of grade 2-3 late gastrointestinal and genitourinary toxicities were 2.3 and 11.4 %, respectively. No patient experienced late grade 4 or higher toxicity. Conclusions: In-room CT-guided 3D-CART was feasible and effective for localized prostate cancer. Treatment outcomes were comparable to those previously reported for intensity-modulated radiotherapy.

AB - Background: We report the feasibility and treatment outcomes of image-guided three-dimensional conformal arc radiotherapy (3D-CART) using a C-arm linear accelerator with a computed tomography (CT) on-rail system for localized prostate cancer. Methods and materials: Between 2006 and 2011, 282 consecutive patients with localized prostate cancer were treated with in-room CT-guided 3D-CART. Biochemical failure was defined as a rise of at least 2.0 ng/ml beyond the nadir prostate-specific antigen level. Toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Results: A total of 261 patients were analyzed retrospectively (median follow-up: 61.6 months). The median prescribed 3D-CART dose was 82 Gy (2 Gy/fraction, dose range: 78-86 Gy), and 193 of the patients additionally received hormonal therapy. The 5-year overall survival rate was 93.9 %. Among low-, intermediate-, and high-risk patients, 5-year rates of freedom from biochemical failure were 100, 91.5 and 90.3 %, respectively. Rates of grade 2-3 late gastrointestinal and genitourinary toxicities were 2.3 and 11.4 %, respectively. No patient experienced late grade 4 or higher toxicity. Conclusions: In-room CT-guided 3D-CART was feasible and effective for localized prostate cancer. Treatment outcomes were comparable to those previously reported for intensity-modulated radiotherapy.

KW - C-arm

KW - Prostate cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84944050229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944050229&partnerID=8YFLogxK

U2 - 10.1186/s13014-015-0515-4

DO - 10.1186/s13014-015-0515-4

M3 - Article

C2 - 26458948

AN - SCOPUS:84944050229

VL - 10

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 208

ER -